The FDA has placed a partial clinical hold on all clinical trials examining venetoclax (Venclexta) in multiple myeloma, halting enrollment of new patients on the studies, according to AbbVie, which jointly develops the BCL-2 inhibitor with Genentech (Roche).
The clinical hold does not affect any of the FDA-approved indications for venetoclax, which include the treatment of patients with chronic lymphocytic leukemia and acute myeloid leukemia. The hold also does not impact clinical studies of the BCL-2 inhibitor for patients with malignancies other than myeloma.
AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program. AbbVie. Published March 19, 2019. Accessed March 19, 2019. https://bit.ly/2Ogtt7M.
... to read the full story